⭐ Study Highlights

Zeng G et al. · Lancet. 2026 Apr 25;407(10539):1626-1638. doi: 10.1016/S0140-6736(26)00367-3. · PMID 42035778

Why it matters: A randomised controlled trial published in Lancet reporting Individuals with chronic kidney disease (CKD), particularly those at more advanced stages, have been systematically under-represented in randomised controlled trials (RCTs) of bloo.

Individuals with chronic kidney disease (CKD), particularly those at more advanced stages, have been systematically under-represented in randomised controlled trials (RCTs) of blood-pressure-lowering treatment due to safety concerns, leading to a persistent paucity of evidence for cardiovascular risk management in this high-risk group.

Mancuso ME et al. · N Engl J Med. 2026 Apr 30;394(17):1696-1709. doi: 10.1056/NEJMoa2517384. · PMID 42054679

Why it matters: A randomised controlled trial published in N Engl J Med reporting Mim8 (denecimig), a bispecific antibody mimicking activated factor VIII, was developed for bleeding prophylaxis in patients with hemophilia A with or without factor VIII inhibitors.

Mim8 (denecimig), a bispecific antibody mimicking activated factor VIII, was developed for bleeding prophylaxis in patients with hemophilia A with or without factor VIII inhibitors. In this phase 3, randomized trial, we assigned patients 12 years of age or older with hemophilia A with or without inhibitors to receive subcutaneous Mim8 once weekly or once monthly at a dose tiered according to body weight and given in a fixed injection volume (0.8 ml).

📑 Index

❤️ Cardiovascular

🫁 Respiratory

⚗️ Endocrinology & Metabolism

🧠 Neurology & Stroke

🧬 Psychiatry

🦠 Infectious Diseases

🔬 Oncology

🩸 Haematology

🫘 Urology & Nephrology

🏥 Gastroenterology & Surgery

💻 AI & Digital Health

🌐 Public Health

🌍 Global Health

📋 Other

Castlebrook Clinical Intelligence · · 2026-05-03

Keep Reading